Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):585-90. doi: 10.1016/j.ijrobp.2013.02.024. Epub 2013 Apr 26.
To evaluate outcomes of conservative surgery and radiation therapy (RT) treatment in patients with dermatofibrosarcoma protuberans.
We retrospectively reviewed the medical records of 53 consecutive dermatofibrosarcoma protuberans patients treated with surgery and preoperative or postoperative radiation therapy between 1972 and 2010. Median tumor size was 4 cm (range, 1-25 cm). Seven patients (13%) were treated with preoperative RT (50-50.4 Gy) and 46 patients (87%) with postoperative RT (60-66 Gy). Of the 46 patients receiving postoperative radiation, 3 (7%) had gross disease, 14 (30%) positive margins, 26 (57%) negative margins, and 3 (7%) uncertain margin status. Radiation dose ranged from 50 to 66 Gy (median dose, 60 Gy).
At a median follow-up time of 6.5 years (range, 0.5 months-23.5 years), 2 patients (4%) had disease recurrence, and 3 patients (6%) had died. Actuarial overall survival was 98% at both 5 and 10 years. Local control was 98% and 93% at 5 and 10 years, respectively. Disease-free survival was 98% and 93% at 5 and 10 years, respectively. The presence of fibrosarcomatous change was not associated with increased risk of local or distant relapse (P=.43). One of the patients with a local recurrence had gross residual disease at the time of RT and despite RT to 65 Gy developed both an in-field recurrence and a nodal and distant recurrence 3 months after RT. The other patient with local recurrence was found to have in-field recurrence 10 years after initial treatment. Thirteen percent of patients had an RT complication at 5 and 10 years, and 9% had a moderate or severe complication at 5 and 10 years.
Dermatofibrosarcoma protuberans is a radioresponsive disease with excellent local control after conservative surgery and radiation therapy. Adjuvant RT should be considered for patients with large or recurrent tumors or when attempts at wide surgical margins would result in significant morbidity.
评估隆突性皮肤纤维肉瘤患者行保守手术联合放射治疗的疗效。
我们回顾性分析了 1972 年至 2010 年间,53 例连续接受手术联合术前或术后放疗的隆突性皮肤纤维肉瘤患者的病历资料。肿瘤的中位大小为 4cm(范围:1-25cm)。7 例患者(13%)接受了术前放疗(50-50.4Gy),46 例患者(87%)接受了术后放疗(60-66Gy)。在接受术后放疗的 46 例患者中,3 例(7%)有肉眼残留病灶,14 例(30%)切缘阳性,26 例(57%)切缘阴性,3 例(7%)切缘状态不确定。放疗剂量为 50-66Gy(中位剂量为 60Gy)。
中位随访时间为 6.5 年(范围:0.5 个月-23.5 年),2 例患者(4%)出现疾病复发,3 例患者(6%)死亡。5 年和 10 年的总生存率分别为 98%。5 年和 10 年的局部控制率分别为 98%和 93%。5 年和 10 年的无病生存率分别为 98%和 93%。纤维肉瘤样变的存在与局部或远处复发的风险增加无关(P=.43)。1 例局部复发患者在放疗时仍有肉眼残留病灶,尽管接受了 65Gy 的放疗,但在放疗后 3 个月时仍出现了局部复发、淋巴结转移和远处转移。另 1 例局部复发患者在初始治疗 10 年后发现局部复发。13%的患者在 5 年和 10 年时发生了放疗并发症,9%的患者在 5 年和 10 年时发生了中度或重度并发症。
隆突性皮肤纤维肉瘤对放射治疗敏感,行保守手术联合放射治疗后局部控制效果良好。对于肿瘤较大或复发的患者,或当广泛手术切除会导致明显的发病率时,应考虑辅助放疗。